Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Severe acute respiratory distress syndrome (ARDS) induced by human adenovirus B21: Report on 2 cases and literature review

Carmen Andrea Pfortmueller a,⁎, Maria Teresa Barbani b, Joerg Christian Schefold a, Elias Hage c, Albert Heim c, Stefan Zimmerli d

Abstract

Severe pneumonia and ARDS caused by human adenovirus B21 infections (HAdV-B21) is a rare, but a devastating disease with rapid progression to multiorgan failure and death. However, only a few cases were reported so far. Infections appear associated with increased disease severity and higher mortality in infected critically ill patients. Possible factors contributing to infection are underlying psychiatric disease resulting in institutionalization of respective patients, and polytoxicomania. Controlled data on the therapy of severe adenovirus infections are lacking and remains experimental.

In conclusion, data on HAdV-B21 infections causing severe pneumonia or ARDS are scarce. Controlled clinical trials on the therapy of adenovirus pneumonia are non existent and thus there is no established therapy so far. ICU physicians should be aware of this potentially devastating disease and further studies are needed.

© 2019 Elsevier Inc. All rights reserved.

Keywords:
Critical illness
Respiratory failure
Viral 21B
HAdV-B21

1. Introduction

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening disease characterized by fluid accumulation in the interstitial and alveolar spaces due to increased vascular permeability resulting from inflammation [1]. Infectious pneumonia is the most common disease leading to ARDS [1–4] with viral pneumonia accounting for approximately 9% of pneumonia cases [1,5]. However, the proportion of viral pneumonia leading to ARDS is unknown [1,5]. Infections with some respiratory viruses are associated with a high incidence of lung injury, ARDS, and increased mortality [1]. They include influenza A H1N1, avian influenza A viruses H5N1 and H7N9, and the SARS and MERS-Coronaviruses [1,6].

Human adenoviruses are a frequent cause of acute upper respiratory tract infection in children and have high respiratory morbidity, in particular in immune-compromised hosts [7–9]. Interestingly, adenoviruses can affect almost all organ systems depending on the adenovirus type and host factors as e.g. immunodeficiency [10,11]. Adenovirus infections are mostly self-limiting in immune-competent patients with treatment mainly relying on supportive measures [10,11]. Life threatening adenovirus infections, e.g. viral pneumonia and ARDS were reported and associated with a few adenovirus types, but appear to be rare [8,11]. These cases are mainly attributed to disseminated infections by adenovirus serotypes 7, 21 and 3, all belonging to subgroup B1 viruses.

Here we report two cases of severe ARDS caused by a highly virulent strain of adenovirus B21, subtype 21a (HAdV-B21) and review the literature on adenovirus-induced ARDS.

1.1. Case 1

A 53 year old male patient was referred to our hospital from an outpatient psychiatric clinic due to upper respiratory tract infection progressing to lower respiratory tract involvement. The patient presented with worsening tachypnoea and increasing respiratory distress. His personal history included paranoid schizophrenia, a history of intravenous drug use with current enrollment in an official drug substitution program, structural epilepsy, and chronic hepatitis C. Amoxicillin with clavulanic acid and clarithromycin was prescribed for suspected pneumonia and he was admitted to the normal ward. Within a short time his respiratory function deteriorated rapidly and he was transferred to the intensive care unit (ICU) for intubation. Antibiotic therapy was escalated to piperacillin/tazobactam. Initially, the patient presented with a clinical picture suggesting septic shock with hyperdynamic cardiocirculatory failure due to marked vasoplegia. Differentiated
Catecholamine and volume therapy was started. Bilateral pleural effusions were drained. Over the ensuing days, his condition stabilized, a decline in inflammation parameters was observed and catecholamine support was stopped. Cultures of respiratory specimens were without growth.

Five days later, a secondary decline in respiratory function was observed and imaging studies were suggestive of ARDS. Lung protective ventilation was initiated, prone positioning performed, and antibiotic therapy was changed to cefepime and metronidazole. Laboratory parameters documented increased systemic inflammation (C-reactive protein, CRP 319 mg/l) and the patient developed pancytopenia (white blood cell count 2.9G/l, hemoglobin 85 g/l, platelet count 32G/l). By PCR high virus loads of HAdV-B21 was detected in plasma and broncho-alveolar lavage (BAL)-fluid.

Despite extensive medical therapy, the patient developed rapidly deteriorating multi-organ dysfunction. The installation of extra corporal membrane (ECMO) support was carefully considered, but decided against. The patient died shortly after being put on comfort care. Autopsy confirmed severe ARDS with bilateral diffuse parenchymal defects and interstitial thickening. Additionally, hemorrhagic infarction of the right upper lobe was noted.

1.2. Case 2

A 35 year old female presented to a regional hospital with a two-week history of lower respiratory tract infection not responding to treatment with amoxicillin with clavulanic acid for 10 days. Her personal history included seropositive rheumatoid arthritis treated with infliximab and leflunomide and borderline psychiatric disease. Despite escalation of antibiotic therapy to piperacillin/tazobactam and non-escalation of antibiotic therapy to piperacillin/tazobactam and non-

...
Rhinovirus, Cytomegalovirus and Herpes simplex virus type 1 all tested negative by qualitative real-time PCR). Blood cultures and routine bacterial cultures also remained negative.

3. Literature review

A systematic literature search was conducted on Medline (www.pubmed.org) with the following MeSH terms “adenovirus B21”, “adenovirus B21 pneumonia”, “adenovirus B21 severe pneumonia” and “adenovirus B21 ARDS”.

The following exclusion criteria were applied: articles not featuring HAdV-B21 infections, articles in languages other than English and German, articles on biological or microbiological aspects of adenovirus infections with no relation to clinical practice, and articles older than 20 years.

Older clinical work was excluded as it has been described that non-virulent strains HAdV-B21 have circulated in Europe between 1960 and 1980 [11].

The literature research resulted in 8 articles related to HAdV-B21 infection. Of these, five publications were excluded because they reported microbiological or technical details with no relation to clinical practice [14-17] or were only available in Russian [18], see Table 1. The remaining papers were used for further evaluation [9,11]. Included papers are summarized in Table 2.

3.1. Clinical aspects

The first paper presents results of a cluster analysis of emergent severe respiratory tract infections caused by adenoviruses in Oregon, USA, from 2013 to 2014 [9]. Ten percent of the patients were infected with HAdV-B21, the third most common type of adenovirus isolated following adenovirus B7 (59%) and C2 (13%).

Table 1

| N | Article | Reason for exclusion | Reference |
|---|---------|----------------------|-----------|
| 1 | Dehghan S, Seto J, Jones MS, Dyer DW, Chodosh J, Seto D. Simian adenovirus type 35 has a recombinant genome comprising human and simian adenovirus sequences, which predicts its potential emergence as a human respiratory pathogen. Virology. 2013;447 (1–2):265–73. | Microbiological aspects | [14] |
| 2 | Barreiro PR, Valinotto LE, Tittarelli E, Mischchenko AS. Molecular typing of adenoviruses in pediatric respiratory infections in Buenos Aires, Argentina (1999–2010). Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2012;53(2):145–50 | Technical aspects | [15] |
| 3 | Seto J, Walsh MP, Metzgar D, Seto D. Computational analysis of adenovirus serotype 5 (HAdV-C5) from an HAdV coinfection shows genome stability after 45 years of circulation. Virology. 2010;404(2):180–6. | Microbiological and technical aspects | [16] |
| 4 | Metzgar D, Gibbons C, Hudson NR, Jones MS. Evaluation of multiplex type-specific real-time PCR assays using the LightCycler and joint biological agent identification and diagnostic system platforms for detection and quantitation of adult human respiratory adenoviruses. Journal of clinical microbiology. 2010;48(4):1397–403. | Technical aspects | [17] |
| 5 | Tsybalova LM, Popova TL, Karpukhin GI. [HLA system antigens in persons with differing susceptibility to the causative agents of acute respiratory diseases]. Zhurnal mikrobiologii, epidemiologii, i immunobiologii. 1989 [10]:64–8. | Article in Russian | [18] |
adenovirus B21 infection were significantly older than those infected with other adenovirus types. HAdV-B21 infections resulted in pneumonia in ≥21% of cases and required hospitalization in 81%. Thirty patients (30%) were admitted to the ICU, 23% required mechanical ventilation. No fatalities were noted.

The second publication describes a case series of 7 cases of HAdV-B21 infections between 2005 and 2013 in Germany [11]. The patients’ age ranged from 2.5 months to 61 years. Four out of seven patients were male [11]. Six patients suffered from severe pneumonia, and one from keratoconjunctivitis. All patients with pneumonia required hospitalization in an ICU for mechanical ventilation, two received ECMO therapy and two others not on ECMO died. Interestingly, four out of seven patients had psychiatric disease (schizophrenia or polytoxicomania), and one patient received immunosuppressants following solid organ and stem cell transplantation.

The third article evaluates data on genotyping of adenovirus infections from 22 US hospitals over 25 month of observation [19]. Infection with HAdV-B21 was associated with an OR of 7.6 for severe disease.

### 3.2. Microbiological aspects

Adenoviridae are ubiquitous DNA viruses. They are associated with respiratory disease, but also gastrointestinal, ophthalmological, cardiac, neurological and genitourinary infections depending on the tropism of the adenovirus type causing the infection [10]. Adenoviridae comprise 7 species pathogenic for humans (A–G), and >80 different adenovirus types were classified [9–11]. Transmission occurs by droplets, via the fecal-oral route, and via contaminated fomites. Viral shedding from the respiratory or gastrointestinal tracts may continue for weeks, even in asymptomatic patients [9]. The incubation period is 5–10 days [10]. In immunocompetent patients, the disease is typically self-limiting [10,11], but persistent infections can be noted in the immune-incompetent host resulting in reactivation and severe disease in case of secondary immunosuppression [20].

HAdV-B21 was first isolated in 1956 from a patient with conjunctivitis [11]. Although HAdV-B21 may occasionally cause conjunctivitis, earlier evidence [21,22] and case reports in children [23,24] showed an association between HAdV-B21 and respiratory tract infections. HAdV-B21 can cause severe (broncho-) pneumonia and ARDS [9,11,19,23,24] and the latter may be associated with the emergence of the new subtype 21a, which was also found in our two cases. Main genetic features of this subtype were a shorter penton “RGD” (Arginine-Glycine-Aspartic acid) loop, which binds to the secondary cellular receptor, and thus might influence tropism and virulence. Moreover, subtype 21a was found to have a recombinant genome with the E4 gene region sequence derived from adenovirus type 3, a frequently observed respiratory pathogen [11].

### 4. Discussion

Even though HAdV-B21 infections are known since 1950’s and have affected major organizations by regular outbreaks such as the US military [25], only few severe infections with HAdV-B21 have been reported [9,11]. After careful evaluation of our cases and previously reported ones, three aspects appear to stand out.

First, HAdV-B21 pneumonia was associated with increased rates of severe lung injury and a fatal outcome [11]. The high virulence of the currently circulating HAdV-B21 may contribute to rapid disease progression. Lack of awareness of treating ICU physicians for the severity of adenoviral lower respiratory tract infection may result in delayed treatment. However, if early treatment of viral ARDS and particularly of HAdV-B21 related disease would make a difference in terms of outcome, remains unclear. The effectiveness of antiviral treatment in patients with viral ARDS, the choice of drug, its dosage and treatment duration, remain an area of debate and research, even in case of the more prevalent influenza virus infections [26–28]. In 2014, a meta-analysis of 29,234 patients by Muthuri and co-authors found a significant reduction of mortality in adult patients with influenza A treated early with neuraminidase inhibitors [29]. The effect on mortality was lower when treatment was delayed and not significant in children [29]. Two recently published studies do not support high-dose treatment with oseltamivir [26,27]. On the other hand, a Cochrane review on prevention and treatment of influenza with neuraminidase inhibitors found no effect on serious influenza complications such as ARDS [30]. There is little evidence to guide treatment of adenovirus-related ARDS. No prospective randomized clinical trials have been performed to date to support the use of any antiviral agent for adenovirus infection [31,32]. Cidofovir and brincidofovir appear to be effective treatments for severe adenovirus infections and are frequently used in immunocompromised patients [31–33], but none of these substances is approved for this indication [34]. Therefore, further research is certainly warranted.

Second, a significant percentage of HAdV-B21 cases had psychiatric diseases (e.g. schizophrenia or drug abuse). It was suggested that a psychiatric disorder may make patients more vulnerable to adenovirus infections because of close contacts with fellow in-patients [35]. Facilitated spread of infection and reduced standards of hygiene may be important with regard to children in day-care facilities [36]. Last but not least patients with psychiatric disorders may be at increased risk for malnourishment [37].

### Table 2

| N | Author (year) | Design | Study population | Total study population | Geographical region | Main findings concerning human adenovirus B21 | R |
|---|---------------|--------|------------------|------------------------|---------------------|-----------------------------------------------|---|
| 1 | Scott M et al. (2016) | Prospective observational registry study | General population with human adenovirus infections | 198 (20 adenovirus B21) | United States | • 10% adenovirus B21 patients were significantly older than others • pneumonia in 21% • hospitalization in 81% • 30% admitted to the ICU | [9] |
| 2 | Hage E et al. (2014) | Observational study | Patients with human adenovirus B21 infections and pneumonia | 6 (6 adenovirus B21) | Germany | • 23% required mechanical ventilation • disease of children and middle aged adults • male predominance • >50% suffered from psychiatric comorbidity • all patients needed ICU admission for mechanical ventilation and • 2 patients needed ECMO therapy • OR = 7.6 for severe disease • longer ICU stay | [11] |
| 3 | Gray et al. (2007) | Observational study | General population with human adenovirus infections | 2237 (32 adenovirus B21) | United States | | [19] |
Third, respiratory adenovirus infections are frequently transmitted by droplets and thus start as upper respiratory tract infections. An adequate response of the patient (e.g., bed rest) may limit or delay spread of the infection to the lower respiratory tract. Pneumotropic adenovirus types may effectively disseminate through the respiratory tract because apical infection of ciliated airway cells is more efficient and subsequently more virus is shed into the airways [38]. Tissue injury may be promoted by proinflammatory cytokines such as IP-10 and I-Tac induced by pneumotropic adenovirus types [38]. Host factors impacting on the occurrence of HAdV-B21 are currently unclear and should be studied in future analyses.

5. Conclusions

Severe pneumonia and ARDS caused by HAdV-B21 infections are rare, but may be fatal. Especially infections due to HAdV-B21 appear associated with increased disease severity and mortality. The reason for the apparently increased risk for severe pulmonary disease in patients with underlying psychiatric disease needs to be elucidated. In patients with severe ARDS in which the disease progresses despite maximal therapy, rare viral infections such as HAdV-B21 should be suspected and evaluated by real time PCR in BAL and plasma fluid.

Controlled data on the therapy of severe adenovirus infections is lacking and the use of antiviral drugs like cidofovir remains experimental. In conclusion, data on HAdV-B21 infections causing severe pneumonia or ARDS are scarce. ICU physicians should be aware of this potentially devastating disease and further studies are needed.

Ethical approval and consent to participate

Not applicable

Consent for publication

All authors consent to publication

Availability of supporting data

Not applicable

Competing interests

The authors declare that they have no competing interest

Authors’ contributions

CAP: designed the strategy, performed the literature review, drafted the first manuscript (clinical part), revision for important intellectual content
MTB: drafted the first manuscript (microbiological part), revision for important intellectual content
JCS: designed the strategy, drafted the manuscript, revision for important intellectual content
EH: Performed the microbiological analysis, revision for important intellectual content
AH: Performed the microbiological analysis, revision for important intellectual content
SZ: Designed the strategy, revision for important intellectual content

Acknowledgements

*Not applicable.

Conflict of interest

None.

Funding

Self-funding.

References

[1] Bauer TT, Ewig S, Rodloff AC, Muller EE. Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data. Clin Infect Dis 2006;43(6): 748–56.
[2] Estenssoro E, Dubin A, Lafaire E, Canales H, Saenz G, Museinico M, et al. Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome. Crit Care Med 2002;30(11):2450–6.
[3] Valta P, Uusaro A, Nunes S, Ruokonen E, Takala J. Acute respiratory distress syndrome: frequency, clinical course, and costs of care. Crit Care Med 1999;27(11): 2367–74.
[4] Luhr OR, Antonsen K, Karlsson M, Aardal S, Thorsteinsson A, Frosteg A, et al. Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF study group. Am J Respir Crit Care Med 1999;159(6):1349–61.
[5] de Roux A, Marcos MA, Garcia E, Mensa J, Ewig S, Lode H, et al. Viral community-acquired pneumonia in nonimmunocompromised adults. Chest 2004;125(4): 1343–51.
[6] Pariani E, Martinelli M, Canuti M, Jazaeri Farsani SM, Oude Munnink BB, Deij J, et al. Influenza and other respiratory viruses involved in severe acute respiratory disease in northern Italy during the pandemic and postpandemic period (2009–2011). Biomed Res Int 2014;2014:241288.
[7] Sun B, He H, Wang Z, Qiu J, Wu X, Ban C, et al. Emergent severe acute respiratory distress syndrome caused by adenovirus type 55 in immunocompetent adults in 2013: a prospective observational study. Crit Care 2014;18(4):456.
[8] Robinsson CM, Singh C, Henquell C, Walsh MP, Peigue-Lafeuille H, Seto D, et al. Computational analysis and identification of an emergent human adenovirus pathogen implicated in a respiratory fatality. Virology 2011;409(2):141–7.
[9] Scott MK, Chommanard C, Lu X, Appelgate D, Grenz L, Schneider E, et al. Human adenovirus associated with severe respiratory infection, Oregon, USA, 2013-2014. Emerg Infect Dis 2016;22(6):1044–51.
[10] Flomenberg P. Adenovirus infections. Medicine 2014;93(2):e42–4.
[11] Hage E, Huzly D, Ganzennueller T, Beck R, Schulz TF, Heim A. A human adenovirus species B subtype 21a associated with severe pneumonia. J Infect 2014;69(5):490–6.
[12] Madisch I, Wolfel R, Harste G, Pommmer H, Heim A. Molecular identification of adenovirus sequences: a rapid scheme for early typing of human adenoviruses in diagnostics samples of immunocompetent and immunodeficient patients. J Med Virol 2006; 78(9):1210–7.
[13] Forstmeyer D, Henke-Gendo C, Brocker V, Wildner O, Heim A. Quantitative temporal and spatial distribution of adenovirus type 2 correlates with disease manifestations and organ failure during disseminated infection. J Med Virol 2008;80(2):294–7.
[14] Debghani S, Seto J, Jones MS, Dyer DW, Chodosh J, Seto D. Simian adenovirus type 35 has a recombinant genome comprising human and simian adenovirus sequences, which predicts its potential emergence as a human respiratory pathogen. Virology 2013;447(1–2):265–73.
[15] Barreiro PR, Valinotto LE, Tittarelli E, Mischenko AS. Molecular typing of adenoviruses in pediatric respiratory infections in Buenos Aires, Argentina (1999-2010). J Clin Virol 2012;53(2):145–50.
[16] Seto J, Walsh MP, Metzgar D, Seto D. Computational analysis of adenovirus serotype 5 (HAdV-C5) from an HAdV coinfection shows genome stability after 45 years of circulation. Virology 2010;404(2):180–6.
[17] Metzgar D, Gibbins C, Hudson NR, Jones MS. Evaluation of multiplex type-specific real-time PCR assays using the LightCycler and joint biological agent identification and diagnostic system platforms for detection and quantitation of adult human respiratory adenoviruses. J Clin Microbiol 2010;48(4):1397–403.
[18] Tsybalova LM, Popova TI, Karpulgin GL. HLA system antigens in persons with differing susceptibility to the causative agents of acute respiratory diseases. Zh Mikrobiol Epidemiol Immunobiol 1989(10):64–8.
[19] Gray GC, McCarthy T, Lebeck MG, Schnurr DP, Russell KL, Kajon AE, et al. Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004–2006. Clin Infect Dis 2007;45(9):1120–31.
[20] Kosulin K, Geiger E, Veceri A, Huber WD, Rauch M, Brenner F, et al. Persistence and reactivation of human adenoviruses in the gastrointestinal tract. Clin Microbiol Infect 2016;22(4) (381.e1–e8).
[21] Van Der Veen J, Dijkman JH, Association of type 21 adenovirus with acute respiratory illness in military recruits. Am J Hyg 1962;76:149–59.
[22] Shultz PA, Polayk F, Dick EC, Warshauer DM, King LA, Mandel AD. Adenovirus 21 infection in an isolated antarctic station: transmission of the virus and susceptibility of the population. Am J Epidemiol 1991;133(6):595–607.
[23] James AG, Lang WR, Liang AH, Mackay RJ, Morris MC, Newman JN, et al. Adenovirus type 21 bronchopneumonia in infants and young children. J Pediatr 1979;95(4): 530–3.
[24] Lang WR, Howden CW, Laws J, Burton JF. Bronchopneumonia with serious sequelae in children with evidence of adenovirus type 21 infection. Br Med J 1969;1(5636): 73–9.
[25] Kajon AE, Hang J, Hawkins P, Metzgar D, Hage E, Hansen CJ, et al. Molecular epidemiology of adenovirus type 21 respiratory strains isolated from US military trainees (1996–2014). J Infect Dis 2015;212(6):871–80.
[26] Noel ZR, Bastin ML, Montgomery AA, Flannery AH. Comparison of high-dose versus standard dose oseltamivir in critically ill patients with influenza. J Intensive Care
Med 2017 Dec;32(10):574–7. https://doi.org/10.1177/0885066616638649 Epub 2016 Mar 18.

[27] Flannery AH, Thompson Bastin ML. Oseltamivir dosing in critically ill patients with severe influenza. Ann Pharmacother 2014;48(8):1011–8.

[28] Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. Ann Pharmacother 1995;29(3):289–310.

[29] Muthuri SG, Venkatesan S, Myles PR, Leonard-Bee J, Al Khawaitir TS, Al Mamun A, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1 pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014;2(5):395–404.

[30] Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase Inhibitors for Preventing and Treating Influenza in Healthy Adults and Children. The Cochrane Database of Systematic Reviews, 4; 2014 (Cd008965).

[31] Florescu MC, Miles CD, Florescu DF. What do we know about adenovirus in renal transplantation? Nephrol Dial Transplant 2013;28(8):2003–10.

[32] Tollefson AE, Spencer JF, Ying B, Buller RM, Wold WS, Toth K. Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model. Antiviral Res 2014;112:38–46.

[33] Grimley MS, Chemaly RF, Englund JA, Kurtzberg J, Chittick G, Brundage TM, et al. Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial. Biol Blood Marrow Transplant 2017;23(3):512–21.

[34] Ison MG, Hayden RT. Adenovirus. Microbiol Spectr 2016;4(4).

[35] Rump B, De Boer M, Reis R, Wassenberg M, Van Steenbergen J. Signs of stigma and poor mental health among carriers of MRSA. J Hosp Infect 2017 Mar;95(3):268–74. https://doi.org/10.1016/j.jhin.2016.09.010 Epub 2016 Sep 17.

[36] Amoah AO, Witherspoon NO, Perodin J, Paulson JA. Findings from a pilot environmental health intervention at early childhood centers in the District of Columbia. J Public Health (Oxf) 2016;38(3):e209-e17.

[37] Oster G, Berger A, Edelsberg J, Weber DJ. Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay, total hospital charges, and mortality. J Med Econ 2013;16(6):809–19.

[38] Lam E, Ramke M, Warnecke G, Schrepler S, Kopfnagel V, Dobner T, et al. Effective apical infection of differentiated human bronchial epithelial cells and induction of proinflammatory chemokines by the highly pneumotropic human adenovirus type 14p1. PLoS One 2015;10(7):e0131201.